Cerebrovascular transport of [125I]quinuclidinyl benzilate, [3H]cyclofoxy, and [14C]iodoantipyrine.
The transport rate constants across rat brain capillaries of a muscarinic acetylcholine receptor antagonist, [125I]quinuclidinyl benzilate (IQNB), an opiate receptor antagonist, [3H]cyclofoxy (CF), and a highly diffusible blood flow indicator, [14C]iodoantipyrine (IAP), were determined by the indicator-diffusion technique and a model that includes a distribution of capillary transit times and a homogeneous distribution of the test compound in the tissue parenchyma. The mean influx extraction ratio (E1) of IAP was greater than 0.91, and E1 for CF and IQNB was 0.56-0.79 and 0.34-0.46, respectively. The order of lipid solubility was IQNB greater than IAP greater than CF; the apparent discrepancy (high lipid solubility and low permeability) of IQNB was partly due to intravascular binding to plasma protein and red blood cells. The observed initial tissue distribution volumes (lambda 1, ml/g brain) for IQNB (0.09-0.17), CF (0.51), and IAP (0.71) were compared with those estimated for the unbound free ligand in blood (lambda a, ml/g brain; IQNB = 1.3-2.3, CF = 0.88, and IAP = 1.4). These findings suggest that the binding of lipid-soluble radioligands and drugs to plasma proteins and red blood cells can be a major determinant of transport across the blood-brain barrier and the apparent distribution volume of the ligand in brain tissue.
Nuclear Medicine Department, National Institute of Health, National Institutes of Mental Health, Bethesda, Maryland 20892.
Y
Y
Sawada
S
S
Hiraga
C S
CS
Patlak
K
K
Ito
K D
KD
Pettigrew
R G
RG
Blasberg
D000818:Animals; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000097:blood; D001692:Biological Transport; D001798:Blood Proteins / Q000378:metabolism; D002196:Capillaries / Q000378:metabolism; D002250:Carbon Radioisotopes; D002560:Cerebrovascular Circulation; D004058:Diffusion; D004912:Erythrocytes / Q000378:metabolism; D007201:Indicator Dilution Techniques; D007457:Iodine Radioisotopes; D008297:Male; D008955:Models, Cardiovascular; D009271:Naltrexone / Q000031:analogs & derivatives* / Q000097:blood; D010539:Permeability; D011812:Quinuclidines / Q000097:blood*; D011813:Quinuclidinyl Benzilate / Q000097:blood*; D051381:Rats; D013997:Time Factors; D014316:Tritium
D001798:Blood Proteins; D002250:Carbon Radioisotopes; D007457:Iodine Radioisotopes; D011812:Quinuclidines; D014316:Tritium; D009271:Naltrexone; D011813:Quinuclidinyl Benzilate; C043394:3-acetyl-6-deoxy-6-fluoronaltrexone; D000983:Antipyrine; C008135:iodoantipyrine